Listen
Reason for request
Inclusion on the lists of medicines refundable by National Health Insurance and approved for hospital use.
-
Clinical Benefit
| Substantial |
The actual benefit of these proprietary products is substantial in the population matching the population which took part in clinical studies, i.e. excluding patients at risk of ovarian hyperstimulation because of a history of ovarian hyperstimulation syndrome or hyper-response, polycystic ovarian syndrome, or antral follicle count of > 20. |
Clinical Added Value
| no clinical added value |
ELONVA does not provide any improvement in actual benefit (IAB V) compared to other gonadotropins indicated for stimulation of multiple follicle growth, including PUREGON, the comparator used in clinical studies. |
English version
Contact Us
Évaluation des médicaments
